Clover Biopharmaceuticals IPO: Needling
Clover is pre-marketing an HKEx IPO to raise proceeds of $300 m. SCB-2019 (CpG 1018/Alum) is a COVID-19 vaccine candidate which was secured CEPI...
377 Views
Clover (äøå¶čēē©) Pre-IPO: COVID-19 Wildcard
We look at Clover's key products, including SCB-2019 (COVID-19 vaccine), SCB-313 (for intracavitary malignancies), and SCB-808 (biosimilar of...
470 Views
ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
620 Views
Clover Biopharmaceutical IPO: Covid-19 Vaccine Candidate Shows Strong Potential
Cloverās most advanced drug asset is a Covid-19 vaccine candidate, SCB-2019 and the company expects to receive conditional approval in the near...
517 Views
Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended
This article mainly analyzed Sirnaomics in terms of the industry characteristics, the delivery platforms, the pipeline and the concerns of the...
448 Views